サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574973

抗不整脈薬市場：薬剤クラス別、投与経路別、適応症別、流通チャネル別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測

Antiarrhythmic Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 311 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
抗不整脈薬市場：薬剤クラス別、投与経路別、適応症別、流通チャネル別、国別、地域別- 産業分析、市場規模、市場シェア、2024年～2032年予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 311 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

抗不整脈薬市場規模は2023年に10億4,732万米ドルとなり、2024年から2032年にかけてCAGR 6.60％で拡大

抗不整脈薬市場- 市場力学

心血管疾患の有病率の上昇が抗不整脈薬市場の成長を促進

心房細動、心室性不整脈、頻脈などの心血管疾患（CVD）の有病率の増加が、抗不整脈薬の需要を促進しています。世界保健機関（WHO）などの報告によると、CVDは依然として死因の第1位であり、年間約1,790万人の命を奪っています。抗不整脈薬は、心臓のリズムを正常に戻し、生命を脅かす合併症を予防する上で重要な役割を果たしています。例えば、アミオダロンとフレカイニドは、不整脈を管理するために一般的に処方されています。政府やヘルスケアプロバイダーは、CVD関連の死亡率を減らすために不整脈の早期診断と治療に注力しており、抗不整脈薬市場に新たな機会を生み出しています。さらに、よりターゲットを絞った治療など、薬剤製剤の進歩がこの分野の成長を支えています。

抗不整脈薬市場-主な洞察

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約6.60%のCAGRで年間成長すると推定されています。

薬剤クラス別では、ナトリウムチャネル遮断薬が2023年に最大の市場シェアを示すと予測されます。

投与経路別では、経口剤が2023年の主要タイプでした。

適応症別では、心房細動が2023年の主要タイプでした。

地域別では、北米が2023年の売上高でトップ

抗不整脈薬市場-セグメンテーション分析：

世界の抗不整脈薬市場は、薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別に区分されます。

薬剤クラス別に4つに分類される：ナトリウムチャネル遮断薬、β遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬です。ナトリウムチャネル遮断薬は不整脈の管理に広く使用されているため、優先順位が最も高く、カリウムチャネル遮断薬とベータ遮断薬がその有効性で知られています。カルシウム拮抗薬の順位はこれらに比べて低かった。

市場は投与経路別に3つのカテゴリーに分けられる：経口剤、注射剤、経皮剤です。経口投与の優先順位は、利便性と患者の嗜好性から経口投与が最も高く、次いで、より早急な治療が必要な注射剤が続く。経皮投与は使用頻度こそ低いもの、特定の条件下で関心が高まっています。

抗不整脈薬市場-地理的洞察

抗不整脈薬市場は、心血管疾患の有病率の高さと強固なヘルスケアインフラを背景に、2023年には北米が首位となるなど、地理的な変動が大きいです。米国心臓協会の報告によると、米国では270万人から610万人近くが心房細動を患っており、これが抗不整脈薬需要の主要な原動力となっています。欧州では、欧州心臓病学会（ESC）の不整脈管理と研究を強化するプログラムのようなイニシアチブに支えられて、これに追随しています。アジア太平洋地域では、急速な都市化とライフスタイルの変化が心血管疾患のリスクを高めており、中国やインドのような国では抗不整脈治療に対する需要が高まっています。アジア太平洋地域はまた、インドのAyushman Bharatスキームのような医療アクセスの改善を目的とした政府プログラムからも恩恵を受けています。ラテンアメリカと中東・アフリカは緩やかな成長を示しており、ヘルスケアインフラへの投資の増加と心臓病治療に対する意識の高まりが、これらの地域における抗不整脈薬需要を促進しています。

抗不整脈薬市場-競合情勢：

抗不整脈薬市場の競合情勢は、北米が技術革新と戦略的提携の面でリードしており、活発な動きを見せています。例えば、米国を拠点とするファイザーやアムジェンなどの製薬大手は、先進的な抗不整脈治療薬の開発で最先端を走ってきました。2022年、ファイザーはブリストル・マイヤーズスクイブとの戦略的提携を発表し、不整脈もターゲットとする心血管治療薬のポートフォリオを拡大しました。サノフィやノバルティスなどの企業が、薬剤の有効性と患者の転帰を改善するための共同研究に積極的に取り組んでいます。最近では、ノバルティスが心房細動の再発抑制を目的とした新薬を欧州市場で発売し、大きなアンメットニーズに取り組んでいます。アジア太平洋地域は、武田薬品のような地域プレーヤーによる研究開発への投資が拡大しており、重要な地域として急速に浮上しています。2023年、武田薬品は心血管治療薬のポートフォリオを拡充するため、現地のバイオテクノロジー企業との合併を発表しており、この地域の抗不整脈薬市場における競争とイノベーションの高まりを示唆しています。

目次

第1章 抗不整脈薬市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 抗不整脈薬の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 抗不整脈薬産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 抗不整脈薬市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 抗不整脈薬市場情勢

  • 抗不整脈薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 抗不整脈薬市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • ナトリウムチャネル遮断薬
    • ベータ遮断薬
    • カリウムチャネル遮断薬
    • カルシウムチャネル遮断薬

第8章 抗不整脈薬市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 注射可能
    • 経皮

第9章 抗不整脈薬市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 心房細動
    • 心室頻拍
    • 上室性頻拍
    • その他

第10章 抗不整脈薬市場- 流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第11章 抗不整脈薬市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 抗不整脈薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Abbott Laboratories
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Harlan Laboratories, Inc.
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV3966

REPORT HIGHLIGHT

Antiarrhythmic Drugs Market size was valued at USD 1,047.32 million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.

The Antiarrhythmic Drugs Market focuses on medications used to treat abnormal heart rhythms (arrhythmias), which are conditions where the heart beats irregularly, too fast, or too slow. These drugs are essential for preventing complications like stroke and heart failure. The increasing prevalence of cardiovascular diseases globally has been a significant growth factor, with atrial fibrillation affecting more than 33 million people worldwide. However, side effects associated with antiarrhythmic drugs and the availability of alternative treatments, such as catheter ablation, act as restraints. Opportunities lie in the development of new and safer antiarrhythmic drugs and the growing demand for minimally invasive treatments. Government health initiatives and rising geriatric populations further support market expansion, particularly in regions like North America and Europe.

Antiarrhythmic Drugs Market- Market Dynamics

Rising Prevalence of Cardiovascular Diseases Fuels Growth in the Antiarrhythmic Drugs Market

The increasing prevalence of cardiovascular diseases (CVDs), such as atrial fibrillation, ventricular arrhythmias, and tachycardia, is driving the demand for antiarrhythmic drugs. Globally, organizations like the World Health Organization (WHO) report that CVDs remain the leading cause of death, responsible for approximately 17.9 million lives annually. Antiarrhythmic drugs play a crucial role in restoring normal heart rhythm and preventing life-threatening complications. For example, Amiodarone and Flecainide are commonly prescribed to manage irregular heartbeats. Governments and healthcare providers are focusing on early diagnosis and treatment of arrhythmias to reduce CVD-related mortality, creating new opportunities in the antiarrhythmic drugs market. Additionally, advancements in drug formulations, such as more targeted therapies, are supporting growth in this sector.

Antiarrhythmic Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)

Based on Drug Class segmentation, Sodium Channel Blockers was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Indication segmentation, Atrial Fibrillation was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Antiarrhythmic Drugs Market- Segmentation Analysis:

The Global Antiarrhythmic Drugs Market is segmented on the basis of Drug Class, Route of Administration, Indication, Distribution Channel, and Region.

The market is divided into four categories based on Drug Class: Sodium Channel Blockers, Beta-Blockers, Potassium Channel Blockers, and Calcium Channel Blockers. Sodium Channel Blockers held the highest priority due to their widespread use in managing arrhythmias, followed by Potassium Channel Blockers and Beta-Blockers, known for their efficacy. Calcium Channel Blockers ranked lower in comparison.

The market is divided into three categories based on the Route of Administration: Oral, Injectable, and Transdermal. Oral administration held the highest priority due to convenience and patient preference, followed by Injectable forms for more immediate treatment needs. Transdermal administration ranked lower in usage but is gaining interest for certain conditions.

Antiarrhythmic Drugs Market- Geographical Insights

The antiarrhythmic drugs market shows significant geographical variation, with North America leading in 2023 due to the high prevalence of cardiovascular diseases and robust healthcare infrastructure. The American Heart Association reports that nearly 2.7 to 6.1 million people in the U.S. suffer from atrial fibrillation, a key driver for antiarrhythmic drug demand. Europe follows closely, supported by initiatives such as the European Society of Cardiology's (ESC) programs to enhance arrhythmia management and research. In Asia-Pacific, rapid urbanization and lifestyle changes have increased the risk of cardiovascular diseases, with countries like China and India witnessing growing demand for antiarrhythmic treatments. The Asia-Pacific region is also benefiting from government programs aimed at improving healthcare access, such as India's Ayushman Bharat scheme, which focuses on providing affordable medical care. Latin America and the Middle East & Africa show moderate growth, with increasing investments in healthcare infrastructure and rising awareness about heart disease treatments fueling demand for antiarrhythmic drugs in these regions.

Antiarrhythmic Drugs Market- Competitive Landscape:

The competitive landscape of the antiarrhythmic drugs market is marked by significant activity, with North America leading in terms of innovation and strategic collaborations. For instance, U.S.-based pharmaceutical giants such as Pfizer and Amgen have been at the forefront of developing advanced antiarrhythmic treatments. In 2022, Pfizer announced a strategic partnership with Bristol-Myers Squibb to expand their portfolio of cardiovascular drugs, which also targets arrhythmias. Europe follows closely, with companies like Sanofi and Novartis actively engaging in research collaborations to improve drug efficacy and patient outcomes. Recently, Novartis launched a new drug in the European market aimed at reducing the recurrence of atrial fibrillation, addressing a significant unmet need. Asia-Pacific is rapidly emerging as a key region, with growing investments in R&D by regional players like Takeda Pharmaceuticals. In 2023, Takeda announced a merger with a local biotech firm to expand its portfolio of cardiovascular drugs, signaling increased competition and innovation in the region's antiarrhythmic drugs market.

Recent Developments:

In May 2024, Milestone Pharmaceuticals Inc. partnered with Arrhythmia Alliance to promote awareness of supraventricular tachycardia (SVT). This collaboration aims to improve education and understanding of the condition, highlighting Milestone's commitment to innovative cardiovascular treatments.

In December 2023, Acesion Pharma, a biotech firm focused on innovative therapies for atrial fibrillation, announced the publication of its Phase 2 proof-of-concept trial results for AP30663, a groundbreaking SK ion channel inhibitor, in Nature Medicine.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIARRHYTHMIC DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Abbott Laboratories
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Harlan Laboratories, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Sodium Channel Blockers
  • Beta-Blockers
  • Potassium Channel Blockers
  • Calcium Channel Blockers

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Atrial Fibrillation
  • Ventricular Tachycardia
  • Supraventricular Tachycardia
  • Other

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL ANTIARRHYTHMIC DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antiarrhythmic Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiarrhythmic Drugs Market Snippet by Drug Class
    • 2.1.2. Antiarrhythmic Drugs Market Snippet by Route of Administration
    • 2.1.3. Antiarrhythmic Drugs Market Snippet by Indication
    • 2.1.4. Antiarrhythmic Drugs Market Snippet by Distribution Channel
    • 2.1.5. Antiarrhythmic Drugs Market Snippet by Country
    • 2.1.6. Antiarrhythmic Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiarrhythmic Drugs Key Market Trends

  • 3.1. Antiarrhythmic Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiarrhythmic Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiarrhythmic Drugs Market Opportunities
  • 3.4. Antiarrhythmic Drugs Market Future Trends

4. Antiarrhythmic Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiarrhythmic Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiarrhythmic Drugs Market Landscape

  • 6.1. Antiarrhythmic Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiarrhythmic Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Sodium Channel Blockers
    • 7.1.3. Beta-Blockers
    • 7.1.4. Potassium Channel Blockers
    • 7.1.5. Calcium Channel Blockers

8. Antiarrhythmic Drugs Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Transdermal

9. Antiarrhythmic Drugs Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Atrial Fibrillation
    • 9.1.3. Ventricular Tachycardia
    • 9.1.4. Supraventricular Tachycardia
    • 9.1.5. Other

10. Antiarrhythmic Drugs Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Antiarrhythmic Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Antiarrhythmic Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Antiarrhythmic Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Antiarrhythmic Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Antiarrhythmic Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Antiarrhythmic Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Antiarrhythmic Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Abbott Laboratories
    • 12.2.2. Amgen Inc.
    • 12.2.3. Astellas Pharma Inc.
    • 12.2.4. AstraZeneca PLC
    • 12.2.5. Bayer AG
    • 12.2.6. Boehringer Ingelheim GmbH
    • 12.2.7. Bristol-Myers Squibb Company
    • 12.2.8. Gilead Sciences, Inc.
    • 12.2.9. GlaxoSmithKline plc
    • 12.2.10. Harlan Laboratories, Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us